Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...

—The initial signs of Duchenne muscular dystrophy in a 3 or 4-year-old child may be subtle, explains Dr. Alexandra Bonner of the Center for Pediatric Neurosciences at Cleveland Clinic. Careful ...

The Food and Drug Administration (FDA) has approved the first gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in children from age 4 through 5 years of age. Pediatric patients who ...

Ad hoc announcement pursuant to Art. 53 LRExclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD ...

While it’s established that Duchenne muscular dystrophy (DMD) causes a loss of muscle mass and strength, few studies have examined the gastrointestinal issues tied to DMD. Initial fractures are the ...

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research. This year’s top stories on Duchenne muscular dystrophy (DMD) managed ...

Duchenne muscular dystrophy (DMD) is a genetic condition that causes increasing muscle weakness over time. While DMD currently has no cure, researchers are studying potential new treatments. When ...

DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of ...

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth ...

Duchenne type muscular dystrophy (DMD) is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of 12 and reducing life expectancy. Researchers have ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study o ...